AbbVie vs Amgen (ABBV vs AMGN)

AbbVie (ABBV) vs Amgen (AMGN) in plain English: P/E, growth, margins, debt and dividend side by side, key differences and which fits each investor profile.

AbbVie (ABBV) and Amgen (AMGN) compete in healthcare and pharma. Here are AbbVie and Amgen side by side with their real figures as of November 4, 2026: what sets them apart, which fits each kind of investor and the most common questions, without telling you whether to buy AbbVie or Amgen.

AbbVie vs Amgen: the figures

AbbVie and Amgen figures from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 4, 2026; N/A means that AbbVie or Amgen figure is not available, and we never estimate it.

3 key differences between AbbVie and Amgen

1. Valuation: AbbVie trades at 50.7x its annual earnings and Amgen at 29.7x; the market pays more for each dollar of AbbVie profit, usually because it expects more growth.
2. Profitability: for every 100 of sales, Amgen keeps 23.0 as net profit and AbbVie keeps 15.7.
3. Volatility: Amgen stock moves more (beta 0.42) than AbbVie (beta 0.19); the higher the beta, the more it amplifies market swings.

AbbVie or Amgen: which fits your profile

• If you want growth: AbbVie is growing faster today, so it fits better with investors who put business growth first, usually accepting a higher P/E and a bumpier ride.
• If you want income (dividends): AbbVie pays the higher dividend relative to its price.
• If you prefer caution: AbbVie has less debt relative to its profit, which usually gives more room in a bad year.
• If price is what matters most to you: Amgen trades on the lower P/E; check first whether that is an opportunity or a sign of a business that grows less.

Neither AbbVie nor Amgen wins on everything, and owning both is also an option: spreading money across several companies or an index fund reduces what rides on each one.

How AbbVie and Amgen make money

AbbVie (ABBV)

AbbVie earns its money from branded drugs grouped into therapeutic areas: Immunology, led by Skyrizi, Rinvoq and Humira, is the biggest, followed by Oncology (Imbruvica, Venclexta), Neuroscience (Vraylar, therapeutic Botox) and Aesthetics (cosmetic Botox, Juvederm). The United States is by far its largest market. Full AbbVie analysis.

Amgen (AMGN)

Amgen is a biotech that sells branded medicines such as Repatha for cholesterol, Prolia and Evenity for bone health, Enbrel and Tezspire for inflammation, and Tepezza and Krystexxa for rare diseases, along with biosimilars. It reports a single segment, and the United States accounts for most of its sales. Full Amgen analysis.

Frequently asked questions: AbbVie vs Amgen

Is AbbVie or Amgen the better stock?

Choosing between AbbVie and Amgen depends on what you are looking for. AbbVie is growing faster right now, and Amgen trades on the lower P/E. Fintols does not tell you whether to buy AbbVie or Amgen: it shows you the differences so you can decide.

Which pays a higher dividend, AbbVie or Amgen?

As of November 4, 2026, AbbVie yields 2.42% and Amgen yields 2.19%. Also check how much of their profit AbbVie and Amgen pay out: if it is more than they earn, it cannot last.

Which is more expensive, AbbVie or Amgen?

On P/E, AbbVie (50.7x) is more expensive than Amgen (29.7x) as of November 4, 2026. A higher P/E can be justified if earnings grow faster, so compare it with each company's growth in the table.

Can I own both AbbVie and Amgen?

Yes. Many people spread their money across several companies, such as AbbVie and Amgen, or use index funds so they do not depend on just one. If you are starting out, decide how much you want to invest and for how long before buying AbbVie or Amgen.

More comparisons with AbbVie or Amgen

• AbbVie vs Abbott
• AbbVie vs Eli Lilly
• Abbott vs Amgen
• Amgen vs Eli Lilly

More companies like AbbVie and Amgen: healthcare and pharma stocks. Educational content about AbbVie and Amgen, not investment advice.